New drug combo shows promise in halting advanced cancers
NCT ID NCT01582191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer growth by blocking key enzymes. The study focused on side effects and tumor response, not on curing the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart shield for young cancer survivors: new study tests dexrazoxane
- New antibody drug aims to turn immune cells against cancer
- One-Shot radiation may ease cancer pain as well as multiple sessions
- Experimental cancer drug AUR106 tested in humans for first time
- Freezing cancer cells: could cryoablation boost immunotherapy?
- Gene-Targeted cancer therapy put to the test in major trial